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Abstract 
Osteoarthritis (OA) is characterised by loss of articular cartilage, synovial membrane 
dysfunction and subchondral sclerosis. Few studies have used a global approach to 
stratify equine synovial fluid (SF) molecular profiles according to OA severity. SF 
was collected from 58 metacarpophalangeal (MCP) and metatarsophalangeal joints 
of racing Thoroughbred horses (Hong Kong Jockey Club; HKJC) and 83 MCP joints 
of mixed breed horses from an abattoir and equine hospital (biobank). Joints were 
histologically and macroscopically assessed for OA severity. For proteomic analysis, 
native SF and SF loaded onto ProteoMiner™ equalisation columns, to deplete high 
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abundant proteins, were analysed using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and label-free quantification. Validation of selected 
differentially expressed proteins was undertaken using clinical SF collected during 
diagnostic investigations. Native SF metabolites were analysed using 1D 1H Nuclear 
Magnetic Resonance (NMR). 1,834 proteins and 40 metabolites were identified in 
equine SF. Afamin levels decreased with synovitis severity and four uncharacterised 
proteins decreased with OA severity. Gelsolin and lipoprotein binding protein 
decreased with OA severity and apolipoprotein A1 levels increased for mild and 
moderate OA. Within the biobank, glutamate levels decreased with OA severity and 
for the HKJC cohort, 2-aminobutyrate, alanine and creatine increased with severity. 
Proteomic and metabolomic integration was undertaken using linear regression via 
Lasso penalisation modelling, incorporating 29 variables (R2=0.82) with principal 
component 2 able to discriminate advanced OA from earlier stages, predominantly 
driven by H9GZQ9, F6ZR63 and alanine. Combining biobank and HKJC datasets, 
discriminant analysis of principal components modelling prediction was good for mild 
OA (90%). This study has stratified equine OA using both metabolomic and 
proteomic SF profiles and identified a panel of markers of interest which may be 
applicable to grading OA severity. This is also the first study to undertake 
computational integration of NMR metabolomic and LC-MS/MS proteomic datasets 
of any biological system.
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Introduction 
The age-related degenerative musculoskeletal condition osteoarthritis (OA) is mainly 
characterised by articular cartilage degradation, synovitis, subchondral bone 
sclerosis and abnormal bone proliferation (1, 2). OA is an important welfare issue for 
equids, with up to 60% of lameness cases attributed to OA, leading to substantial 
morbidity and mortality (3–5). Although it is known that degradation of the 
extracellular matrix (ECM) is driven by increased enzymatic activity of multiple matrix 
metalloproteinases (MMPs) and a disintegrin and metalloproteinases with 
thrombospondin motifs (ADAMTSs), the underlying pathogenesis of OA is yet to be 
fully understood (6–8). Currently, equine OA is predominantly diagnosed through 
radiography, however due to the slow onset of the condition this often leads to 
substantial pathology of the joint and articular cartilage degradation prior to diagnosis 
(9). There is therefore a need to develop accurate biomarkers of early OA which can 
be applied to a clinical setting and allow for timely intervention, as well as improving 
our understanding of OA pathogenesis and identifying potentially novel therapeutic 
targets. 
Currently, no equine OA-specific biomarkers have been identified to aid an early 
clinical diagnosis (10). For human OA diagnosis, increased synovial fluid (SF) 
abundances of both matrix metalloproteinases (MMPs) and cartilage oligomeric 
matrix protein (COMP) have been identified as markers of interest (11). For horses, 
MMP activity has also shown OA diagnostic potential, however studies investigating 
COMP levels have shown conflicting results with SF COMP abundance unable to 
stage equine OA (12–19). However, these markers are generated following 
significant joint pathology, including substantial articular cartilage degradation, and 
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thus there is a need to identify markers at an earlier disease stage, when 
intervention would be most beneficial. 
Palmar/plantar osteochondral disease (POD), located at the distal condyles of 
metacarpal III and metatarsal III, is a highly prevalent pathology of racehorses, 
resultant of repetitive joint overload during cyclic locomotion at high-speed (20–22). 
POD lesions range in severity, from mild to end-stage disease, and as the disease 
originates within the subchondral bone, provides an effective model to investigate 
subchondral bone mediated OA (23). 
The inner layer of the joint capsule consists of a one-cell thick lining of synoviocytes 
within a hyaluronic acid and collagen matrix, called the synovial membrane, which 
produces SF (24, 25). SF primarily acts as a lubricant within the joint, protecting 
hyaline articular cartilage surfaces (26). However, SF also provides a pool of 
nutrients for surrounding tissues and a medium of cellular communication with the 
semi-permeable synovial membrane allowing passive protein transfer and 
synoviocytes secreting regulatory cytokines and growth factors (24–28). Due to the 
close relationship, both in terms of location and biological communication that SF 
holds with surrounding tissues which are primarily altered during OA, and its 
accessibility, SF can provide a unique source of chemical information and holds 
great promise for biomarker discovery (10, 29). 
Various studies have utilised 1H nuclear magnetic resonance (NMR) to investigate 
metabolite markers associated with OA in various species, including pigs, dogs, 
humans and horses (10, 30–35). Lacitignola et al. identified a panel of ten 
metabolites which were elevated in equine OA SF compared to a normal control 
group. This panel included alanine, acetate, N-acetyl glucosamine, pyruvate, citrate, 
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creatine/creatinine, choline, glycerol, lactate and α-glucose. However, no studies to 
date have used 1H NMR to stratify OA to identify changes to the metabolite profile at 
different stages of OA severity. 
Several studies have used mass spectrometry (MS) based methodologies to 
investigate equine OA SF (36–40). The relatively recent development of liquid 
chromatography tandem mass spectrometry (LC-MS/MS) has enabled a method 
which can quickly, with high sensitivity, quantify proteins present within biological 
fluids of high complexity (25). Protein biomarker discovery is however hindered by 
the large protein concentration dynamic range exhibited by SF, meaning that highly 
abundant proteins can mask those of less abundance (41, 42). ProteoMinerTM 
protein enrichment columns (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) 
have however been developed which utilise combinational ligand library technology, 
depleting highly abundant proteins and subsequently enriching low abundance 
proteins to reduce this dynamic range (43–45). This methodology has successfully 
been used to investigate OA in equine SF (38). However, this technique has not yet 
been utilised with SF to enable OA stratification, analysing SF at different OA 
severities. 
Increased activity of MMPs, ADAMTSs, cathepsins and serine proteases during OA 
leads to cartilage breakdown and the generation of OA-specific peptide degradation 
products (neopeptides) (46–48). Numerous studies investigating equine tissue have 
identified potential OA neopeptides of interest using ex-vivo cartilage and SF (37, 38, 
46, 49). As OA neopeptides have also been shown to be a driver of OA pain, 
identification and quantification of neopeptides has the potential to stratify OA, 
providing markers of early OA pathology and providing potential novel OA 
therapeutic and analgesic targets (50). 
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Within this study we have interrogated equine SF from horses with naturally 
occurring OA and those exhibiting POD pathology, as a subchondral bone mediated 
OA model using both 1H NMR metabolomics and LC-MS/MS proteomics to stratify 
equine OA. This is the first study to use both techniques on the same samples and 
the first to statistically integrate NMR-led metabolomics with MS-based proteomics. 
Experimental Procedures 
Experimental Design and Statistical Rationale 
A total of 141 separate equine SF samples were analysed during this study. 
Depending on the analysis undertaken, biological replicates ranged from n=8-34 per 
group for OA grading and n=17-38 per group for synovitis grading (Table 1). Joints 
with a microscopic or macroscopic OA grade of 0 were considered the control group, 
ranging from n=8-17. Metabolite and protein abundances were analysed by t-test or 
ANOVA, depending on the number of groups, with p values corrected for multiple 
testing using the Benjamini-Hochberg false discovery rate method. For NMR 
metabolomics and LC-MS/MS proteomics dataset integration, the Mahalanobis 
distance on principal components was calculated and Chi-squared testing 
undertaken to identify potential outliers. A linear regression, using Lasso (least 
absolute shrinkage and selection operator) penalisation to select the most important 
variables, was applied to combined datasets for both the biobank and Hong Kong 
Jockey Club (HKJC) sample groups. Additionally, correlations of all variables 
(proteins and metabolites) with macroscopic OA score were calculated, with 
significant variables (p < 0.05) included for further analysis. Significant variables 
across all analyses were then selected in a dataset, combining both biobank and 
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HKJC results, and discriminant analysis of principal components (DAPC) was used 
to predict different levels of disease severity.  
Sample Collection and Processing 
Equine post mortem samples were collected from a commercial abattoir, The Philip 
Leverhulme Equine Hospital, University of Liverpool and The Hong Kong Jockey 
Club (HKJC) Equine Hospital. Abattoir and Philip Leverhulme Equine Hospital 
samples were collected from horses of mixed breed and sex and represented 
naturally occurring OA disease. HKJC samples were exclusively from Thoroughbred 
racehorses (aged 3-10 years old) with a high prevalence of POD, providing a model 
for subchondral bone mediated OA. 
University of Liverpool Biobank 
Following euthanasia at the abattoir (F Drury & Sons, Swindon, UK) distal equine 
forelimbs were transported to the University of Liverpool. Horses euthanised at the 
Philip Leverhulme Equine Hospital, University of Liverpool, were processed on site. 
Within 8 hr of euthanasia the metacarpophalangeal (MCP) joint was opened 
aseptically and the distal metacarpal III photographed. SF was removed using a 10 
ml syringe, transferred to a plain eppendorf, centrifuged at 2,540g and 4˚C for 5 min, 
supernatant removed, snap frozen in liquid nitrogen and stored at -80˚C (51) (Figure 
S1). SF was separated into separate 1 ml eppendorfs prior to snap freezing to 
optimise study design prior to multi ‘omics’ analysis and integration (52). Wedge 
sections of articular cartilage/subchondral bone (measuring 4.0 cm x 1.5 cm x 0.5 
cm) were also sampled from the distal condylar region of metacarpal III, lateral to the 
sagittal ridge, and placed into 4% paraformaldehyde (PFA, Sigma-Aldrich, 
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Gillingham, UK) in phosphate buffered saline (PBS, Sigma-Aldrich) (Figure S2). 
Following decalcification in ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich), 
these were then sectioned and stained with Haematoxylin and eosin (H & E) (TCS 
Biosciences Ltd, Buckingham, UK) and Safranin O (BDH Chemicals, Poole, UK). 
As biobank samples were obtained from a commercial abattoir and equine hospital, 
horses sampled were of mixed breed and sex and represented naturally occurring 
OA disease. 
Hong Kong Jockey Club 
HKJC samples were collected using the same collection protocols as used for the 
University of Liverpool equine biobank. In addition, synovial membranes were also 
dissected, fixed in 4% PFA and processed to prepare H & E stained histology slides. 
For HKJC samples, both MCP and metatarsophalangeal (MTP) joints were sampled. 
Following snap freezing with liquid nitrogen, frozen SF samples were shipped to 
Liverpool on dry ice. 
Clinical Synovial Fluid Collection for ELISA 
During clinical diagnostic investigations of horses presenting to The Philip 
Leverhulme Equine Hospital, University of Liverpool between 2014 and 2017, excess 
aspirated SF from live horses was collected and subsequently processed using the 
same processing steps as used for biobank and HKJC SF samples. Clinical OA was 
diagnosed via clinical examination, radiography and/or arthroscopy. Healthy/control 
SF samples were collected during clinical examinations, including diagnostic 
analgesia, whereby the joint involved was not identified as the cause of the current 
lameness. However, underlying joint pathology, not leading to a clinical 
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manifestation, could not be ruled out. These clinical SF samples were used for 
enzyme-linked immunosorbent assay (ELISA) validations of altered protein 
abundances. 
Osteoarthritis Pathology: Macroscopic and Microscopic Scoring 
Biobank distal metacarpal III articular surfaces were assessed for macroscopic OA 
pathology using the equine OARSI scoring scale (53). Histological sections were 
also assessed for microscopic OA related pathology using the microscopic aspect of 
the equine OARSI scoring scale. Within the HKJC group, distal metacarpal III 
samples were assessed macroscopically and microscopically for OA related and 
POD pathology using separate published scoring scales (21, 54). Marginal 
remodelling and dorsal impact injury categories were excluded from the macroscopic 
scoring scale as these could not be scored using the joint photographs which were 
provided. Synovial membrane histological sections were also scored according to 
synovitis severity (55). 
Metabolomics 
NMR Sample Preparation 
SF was thawed over ice and centrifuged for 15 min at 13,000g and 4°C. 150 µl of 
supernatant was then diluted to produce a final volume containing 50% (v/v) SF, 
40% (v/v) dd 1H2O, 100 mM PO43- pH 7.4 buffer (Na2HPO4, VWR International Ltd., 
Radnor, Pennsylvania, USA and NaH2PO4, Sigma-Aldrich) in deuterium oxide (2H2O, 
Sigma-Aldrich) and 0.0025% (v/v) sodium azide (NaN3, Sigma-Aldrich). Prepared 
samples were then vortexed for 1 min, centrifuged for 2 min at 13,000g and 4˚C and, 
using a glass pipette, 195 µl transferred into 3 mm outer diameter NMR tubes. 
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NMR Acquisition 
All SF samples were individually analysed. A 700 MHz NMR Bruker Avance III HD 
spectrometer with associated TCI cryoprobe and chilled Sample-Jet autosampler 
was used to acquire all spectra. 1D 1H NMR spectra, using a Carr-Purcell-Meiboom-
Gill (CPMG) filter to attenuate macromolecule (e.g. protein) signals, were acquired 
using a standard cpmgpr1d vendor pulse sequence. Spectral acquisition was carried 
out at 37˚C with a 4 s interscan delay, 32 transients and a 15 ppm spectral width. 
Software programmes Topsin 3.1 and IconNMR 4.6.7 were used for acquisition and 
processing, carrying out automated phasing, baseline correction and a standard 
vendor processing routine (exponential window function with 0.3 Hz line broadening). 
Metabolite Annotation and Identification 
All 1D 1H NMR spectra were scrutinised to make sure that the minimum reporting 
standards were met, as outlined by the Metabolomics Society (56). These quality 
control criteria included flat baseline correction, water suppression, and consistent 
line widths. Spectra which did not meet these minimum requirements were removed 
from all subsequent analyses. Spectra were aligned to a single formate peak at 8.46 
ppm. Chenomx NMR Suite 8.2 (330-mammalian metabolite library) software was 
used to carry out metabolite annotations and relative abundances. Metabolite 
identifications were confirmed where possible using in-house 1D 1H NMR metabolite 
spectral library standards. 
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Proteomics 
Synovial Fluid Processing and Protein Assay  
SF was thawed on ice and centrifuged at 4°C at 14,000g for 10 min. The supernatant 
was treated with 1µg/ml of hyaluronidase (bovine origin, Sigma-Aldrich) at 37˚C for 1 
hr, centrifuged at 1,000g for 5 min, supernatant removed and 1 ml centrifuged 
through a polypropylene microcentrifuge tube filter with 0.22 µm pore cellulose 
acetate membrane (Costar Spin-X, Corning, Tokyo, Japan) at 5,000g for 15 min to 
remove remaining insoluble particulates (29). A Pierce® 660 nm protein assay 
(Thermo Scientific, Waltham, Massachusetts, USA) was used to determine SF 
protein concentrations. 
ProteoMinerTM Column Processing 
2 mg of protein was loaded onto ProteoMiner™ Small Capacity bead columns (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK) to achieve peptide-based depletion 
of the most abundant proteins. SF samples were rotated for 2 hr at room 
temperature and centrifuged at 1,000g for 60 s. ProteoMinerTM beads were then 
washed in PBS, rotated for 5 min and centrifuged at 1,000g for 60 s. The wash step 
was repeated two further times. 
Protein Digestion 
To assess both high and low abundance synovial proteins, both native and 
ProteoMinerTM processed SF were analysed. For native SF, 100 µg of protein was 
used for each protein trypsin digestion. 25 mM ammonium bicarbonate (Fluka 
Chemicals Ltd., Gillingham, UK) containing 0.05% (w/v) RapiGest (Waters, Elstree, 
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Hertfordshire, UK) was added to both native SF and peptide bound ProteoMinerTM 
beads to produce a final volume of 160 µl and heated at 80°C for 10 min. DL-
Dithiothreitol (Sigma-Aldrich) was added (3 mM final concentration) and incubated at 
60°C for 10 min. Iodoacetamide (Sigma-Aldrich) was added (9 mM final 
concentration) and incubated at room temperature for 30 min in the dark. 
ProteoMinerTM processed samples then underwent an additional step which entailed 
the addition of 2 µg of Lys-C endopeptidase (FUJIFILM Wako Pure Chemical, 
Osaka, Japan) and incubation at 37˚C for 4 hr (51). 2 µg of proteomics grade trypsin 
(Sigma-Aldrich) was added to all samples and rotated for 16 hr at 37°C, followed by 
a second trypsin supplementation for 2 hr incubation. Digests were centrifuged at 
1,000g for 1 min, supernatant removed, trifluoroacetic acid (TFA, Sigma-Aldrich) 
added (0.5% (v/v) final concentration) and rotated for 30 min at 37°C. Digests were 
then centrifuged at 13,000g for 15 min at 4°C and the supernatant removed and 
stored at -80°C. To ensure complete protein digestion, 5 µl of each digest was 
analysed by 1D SDS PAGE and stained with either Coomassie Blue (Bio-Rad) or 
silver stain (Thermo Scientific) following manufacturer instructions (data not shown). 
Sample Processing for Neopeptide Analysis 
After 4 hr of the 16 hr tryptic digestion of ProteoMinerTM processed samples, 10 µl 
was removed and supplemented with TFA and stored at -80°C using the same 
protocol as mentioned above.  
Label Free LC-MS/MS 
All SF digest samples underwent randomisation and were individually analysed 
using LC-MS/MS on an UltiMate 3000 Nano LC System (Dionex/Thermo Scientific) 
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coupled to a Q ExactiveTM Quadrupole-Orbitrap instrument (Thermo Scientific). Full 
LC-MS/MS instrument methods are described in the supplemental data. Tryptic 
peptides, which were equivalent to 200 ng of protein, were loaded onto the column 
and run over 60 min, 90 min and 120 min LC gradients for 4 hr Lys-C + 4 hr tryptic 
digest ProteoMinerTM samples, native SF and 4 hr Lys-C + 16 hr + 2 hr tryptic digest 
ProteoMinerTM processed samples respectively. Representative ion chromatograms 
are shown in Figure S3. 
LC-MS/MS Spectra Processing and Protein Identification 
Progenesis™ QI 2.0 (Nonlinear Dynamics, Waters) software was used to process 
raw spectral files and undertake spectral alignment, peak picking, total protein 
abundance normalisation and peptide/protein quantification. The top ten spectra for 
each feature were then exported with peptide and protein identifications carried out 
with PEAKS® Studio 8.0 (Bioinformatics Solutions Inc., Waterloo, Ontario, Canada) 
using the reviewed Equus caballus database (downloaded 29th July 2016, 22,694 
sequences). Search parameters included: precursor mass error tolerance, 10.0 ppm; 
fragment mass error tolerance, 0.01 Da; precursor mass search type, monoisotopic; 
enzyme, trypsin; maximum missed cleavages, 1; non-specific cleavage, none; fixed 
modifications, carbamidomethylation; variable modifications, oxidation or 
hydroxylation and oxidation (methionine). The false discovery rate (FDR) was set to 
1% with only proteins identified with > 2 unique peptides used for quantitation. 
Semi-Tryptic Peptide Identification 
A ‘semi-tryptic’ search was undertaken to identify potential synovial neopeptides. 
PEAKS® search parameters were kept the same as those used for protein 
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identifications, apart from ‘Non-specific Cleavage’ which was changed from ‘none’ to 
‘one’. The exported ‘peptide ion measurements’ file from Progenesis™ was then 
analysed using an online neopeptide analyser software tool to identify only semi-
tryptic peptides and perform normalisation (57). 
Batch Corrections 
ProteoMinerTM processed samples for both the biobank and HKJC cohorts were run 
in three separate batches on the Q ExactiveTM for protein analysis. To eliminate 
batch effects on the final analysis, a COMBAT batch correction was applied (Figure 
S4) (58). Metabolomic spectra were also acquired over 3 batches for both biobank 
and HKJC cohorts and data also underwent COMBAT batch correction.  
ELISA Protein Validations 
Differentially expressed proteins apolipoprotein A1 (ApoA1), gelsolin and 
lipopolysaccharide binding protein (LBP) were selected for ELISA as commercially 
available kits were compatible with equine samples. Equine ApoA1 (MBS034194, 
MyBioSource Inc., San Diego, California, USA) and equine LBP (MBS062216, 
MyBioSource) utilised sandwich ELISA technology using undiluted SF whilst equine 
gelsolin (CSB-EL009965HO, Cusabio Technology LLC, Houston, Texas, USA) was 
a competitive inhibition assay with SF diluted 1:1250. 3-6 dependent (and 
independent where stated) SF samples were analysed per group. Aliquots of 100 µl 
were analysed in duplicate for each sample with absorbance measured at 450 nm 
and protein concentrations calculated from assay standard curves. Protein 
concentrations were normalised to total protein. 
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Separate Dataset Statistical Analysis 
SF metabolite abundances underwent median normalisation and protein 
abundances were normalised to the total ion current (TIC). Before multivariate 
analysis, both metabolite and protein datasets underwent Pareto scaling (59). All 
principal component analysis (PCA), ANOVA and t-tests of metabolite, protein and 
neopeptide abundances were conducted using MetaboAnalyst 4.0 
(http://www.metaboanalyst.ca). ELISA t-tests and ANOVAs were performed using 
Minitab version 17. For protein analysis an additional filter of > 2 fold abundance was 
implemented. A p value of < 0.05 was considered statistically significant following 
correction for multiple testing using the Benjamini-Hochberg false discovery rate 
method (60). All box plots were produced using SPSS 24. 
NMR metabolomics and LC-MS/MS Proteomics Integration 
Metabolomics and proteomics datasets were initially integrated and analysed 
separately for the biobank and HKJC, then finally all datasets integrated to produce 
an overall model. 
Only datasets for horses which had both metabolite and protein abundance values 
were used for integration. Proteomics datasets were again normalised to the TIC 
whilst NMR datasets were normalised via probabilistic quotient normalisation (PQN) 
(61). When combining ProteoMinerTM processed SF and native SF protein 
abundances for the same SF sample, in which the same protein had been identified 
in both datasets, the higher abundance was included for analysis. The Mahalanobis 
distance on principal components was calculated and Chi-squared testing 
undertaken to identify potential outliers. When combining metabolite and protein 
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variables, categorisation was carried out in accordance to macroscopic OA scoring. 
A linear regression, using Lasso penalisation to select the most important variables, 
was applied to combined datasets for both the biobank and HKJC sample groups. 
Additionally, correlations of all variables (proteins and metabolites) with macroscopic 
OA score were calculated using the Spearman coefficient, with significant variables 
after correcting for False Discovery Rate (Adjusted p value < 0.05) included for 
further analysis. Significant variables across all analyses were then applied to a 
collective dataset, combing both biobank and HKJC results. This dataset was 
stratified into healthy, mild OA and severe OA and a DAPC model was created to 
predict the disease severity. The number of parameters of the model were chosen 
after a cross-validation process calculated using the function xvalDapc and splitting 
the data into train/test subsets at a 80%/20% proportion respectively.  All integration 
analyses were undertaken using standard analytical routines within the software R  
and packages adegenet, ggplot2 and reshape (62–65). 
Uncharacterised Proteins 
Within this study, proteins which were considered uncharacterised were also 
analysed using BLAST (Basic local alignment search tool) to assess similarity of 
their amino acid sequence to characterised proteins within the Equus caballus 
database as well as other species (66). Search parameters included: Matrix, 
blosum62; threshold, 0.1 E; filtering, none; gapped, true. 
Pathway Analysis 
Pathway analysis was conducted on proteins and metabolites which were 
considered significant variables for DAPC when carrying out NMR metabolomic and 
Stratification of Equine Osteoarthritis 
18 
 
LC-MS/MS proteomic dataset integration. Metabolite pathway analysis was 
conducted using the online tool KEGG for Equus caballus with protein pathways also 
analysed using KEGG, via the STRING database (67, 68). A filter of a minimum of 
two metabolites or proteins was set for inclusion of the relevant biological pathway. 
Results 
Stratification Groups 
Histological microscopic OA scores vs macroscopic scores for biobank and HKJC 
samples both showed a weak positive correlation with R2 coefficient values of 0.12 
and 0.17 respectively (Figure S5). Joints were assigned into severity groups 
according to microscopic OA pathology, macroscopic OA pathology and synovitis 
scores (Table 1). Although scored using different scoring systems, overall the HKJC 
samples exhibited a more severe OA phenotype. Macroscopically, scores were on 
average 30% of the highest possible score, compared to 14% within the biobank and 
microscopic scores 31% compared to 15% within the biobank. All scoring is shown in 
Tables S6-S10. Overall, the HKJC dataset was a younger cohort than the biobank 
cohort, with average ages of 6.6 ± 1.9 years and 14.3 ± 7.6 years respectively (Table 
S1). 
NMR Metabolomics 
Overall, both the biobank and HKJC SF 1D 1H NMR spectra produced similar 
profiles, although quantile plots revealed the biobank group exhibited more variation 
between samples (Figure S6). In total, 40 metabolites were identified within equine 
SF (Table 2). For the biobank cohort, unsupervised multivariate PCA did not identify 
separation between OA grades based on microscopic or macroscopic scoring 
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(Figure 1). However, when stratified according to macroscopic grade, glutamate 
levels were found to be differentially abundant, with lower levels identified at grades 
2 and 3 compared to 1. PCA also did not identify clear separation between severity 
grades of OA or synovitis for HKJC SF samples (Figure 2). When stratified according 
to macroscopic OA pathology, three metabolites were found to be differentially 
abundant. 2-aminobutyrate levels were increased at grades 1 and 2 compared to 0 
and alanine and creatine levels were increased with OA severity. 
LC-MS/MS Proteomics 
Within the biobank cohort, 74 native SF samples were analysed with 68 of these 
additionally processed using ProteoMinerTM columns. For the HKJC group, 56 native 
SF samples were analysed with 55 of these additionally having also undergone 
ProteoMinerTM processing. In total, across all samples, 1,834 proteins were identified 
(Figure 3). A combination of an increase in LC gradient length and ProteoMinerTM 
processing resulted in a 168% increase in the overall number of identified proteins 
compared to native SF analysis. 
Following PCA analyses, HKJC native SF samples 95 and 122 were identified as 
outliers and removed from further analyses. For biobank and HKJC groups, when 
categorised according to macroscopic OA severity, PCA identified that increased OA 
severity resulted in less variation between samples (Figure 4). However, this was not 
evident when categorised according to microscopic OA grading. For native SF 
biobank samples categorised according to macroscopic grading, the abundance of 
three uncharacterised proteins and immunoglobulin kappa constant decreased with 
increasing OA severity. An uncharacterised protein (a member of the superfamily 
containing a leucine-rich repeat) and ApoA1 abundances both increased initially with 
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OA pathology but then returned towards baseline with greater OA severity. 
Microscopic OA categorisation for native SF biobank as well as macroscopic and 
microscopic OA categorisation of native SF HKJC samples did not identify any 
differentially abundant proteins. The proteomes of native SF HKJC samples, 
categorised according to synovitis grade, were not separated via PCA (Figure 5). 
However, the abundance of afamin was identified as differentially abundant between 
low and high grade synovitis, decreasing with synovitis severity. ProteoMinerTM 
processing of both biobank and HKJC SF did not identify any differentially abundant 
proteins or distinct proteome clusters (PCA) for any OA or synovitis categorisations 
(Figures S7 and S8). However, LC-MS/MS analysis of ProteoMinerTM processed 
biobank SF identified trends in gelsolin and LBP abundance, decreasing with 
increasing OA severity (Figure 6). ELISA analysis of gelsolin using the same SF 
samples that were analysed by LC-MS/MS corroborated this finding and was 
additionally supported by an independent clinical cohort, with gelsolin abundance 
lower in clinical OA cases compared to controls. LBP ELISA analysis of both 
dependent and independent SF samples also supported the trend identified via LC-
MS/MS, although statistical significance was not reached. For biobank native and 
ProteoMinerTM processed SF we identified a trend that ApoA1 increased initially with 
OA severity and subsequently decreased. This trend was supported by ApoA1 
ELISA analysis using dependent SF samples; however statistical significance was 
not reached. 
Semi-Tryptic Peptide Profiles 
No semi-tryptic peptides arising from ECM proteins were identified which were more 
highly abundant at more severe OA levels and thus no potential neopeptide 
Stratification of Equine Osteoarthritis 
21 
 
biomarkers were identified. Neither for the biobank or HKJC groups were distinct 
profiles identified between severities of OA (Figure S9). For the HKJC group there 
was less intra-group variation identified with increased levels of OA and synovitis 
pathology. However, conversely for the biobank group, samples with no OA 
pathology showed the least variation.  
NMR metabolomics and LC-MS/MS Proteomics Integration 
For the HKJC dataset, linear regression using Lasso penalisation modelling was 
unable to select a suitable number of parameters without overfitting the model. 
However, correlation analysis of all variables (proteins and metabolites) identified 58 
significant variables, with a range in correlation from -0.48 to 0.42 (Table S2). Using 
these selected variables, PCA identified less variation between samples with more 
severe macroscopic OA scores, although their grouping could not clearly be 
distinguished from lower scoring samples (Figure 7).  
For the biobank dataset, Lasso penalisation produced a model incorporating 29 
variables (Table S3). This produced a good model (R2 = 0.82) with PC2 able to 
discriminate more advanced stages of OA from the earlier stages (Figure 8). This 
model was predominantly driven by two uncharacterised proteins (H9GZQ9 and 
F6ZR63) and alanine. Correlation analysis of all variables (proteins and metabolites) 
identified 32 significant variables, with a range in correlation from -0.44 to 0.49 
(Table S4).  
Combining both the biobank and HKJC datasets, including significant protein and 
metabolite variables, DAPC analysis produced a model whereby OA severity 
prediction was good for mild OA (90%) although this was reduced significantly for 
healthy (57%) and severe OA (35%) classifications (Figure 9). Linear discriminant 1 
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was driven predominantly by neural EGFL like 2, serum albumin and alanine whilst 
linear discriminant 2 was driven by periostin, gelsolin and myocilin. 
Uncharacterised Proteins 
BLAST analysis of amino acid sequences of 12 uncharacterised proteins included 
within this study identified various related characterised proteins. The characterised 
protein with the highest percentage amino acid sequence similarity for each 
uncharacterised protein is shown in Table S5. 
Pathway Analysis 
Pathway analysis conducted on proteins and metabolites which were considered 
significant variables during DAPC modelling, when carrying out NMR metabolomic 
and LC-MS/MS proteomic dataset integration, identified the complement and 
coagulation cascades pathway and ABC transporters pathway to be the most 
represented (Tables 3 and 4). These pathways consisted of 7/96 proteins and 4/9 
metabolites included within the pathway analysis respectively. 
 
Discussion 
Equine OA is currently predominantly diagnosed through radiography and clinical 
examination, however, due to the slow onset of the condition this often leads to 
substantial pathology of the joint and articular cartilage degradation prior to diagnosis 
(9). Presently, no equine OA-specific biomarkers have been identified which are able 
to accurately diagnose and stratify OA with none used to aid an earlier clinical 
diagnosis (10). Within this study we have investigated equine SF of varying 
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severities of associated OA pathology using both NMR-led metabolomics and MS-
based proteomics approaches. 
Although both the biobank and HKJC datasets produced a degree of OA 
stratification, markers of interest were generally distinct. This may be reflective of the 
more severe OA phenotype demonstrated by the HKJC horses, whilst markers 
identified within the biobank represent a less severe form of OA. Alternatively, the 
differences in markers identified may be due to the varying OA aetiologies, with the 
biobank representing a naturally occurring OA whilst the HKJC horses demonstrate 
a POD model for subchondral bone mediated OA, which is associated with trauma 
and overload (23). Additionally, the biobank cohort is on average an older donor 
group than the HKJC cohort which may also account for differences between the 
datasets. 1H NMR SF spectra were more variable between biobank donors 
compared to the HKJC donors. This is likely because the biobank is a more 
heterogeneous population, including age, breed, work loads and diet. The HKJC 
group is a much more controlled sample set, with all horses housed together, all 
Thoroughbred racehorses, generally fed and trained similarly and all of a similar age 
at euthanasia. These differentials may also reflect the different markers of interest 
identified between the biobank and HKJC groups. 
Proteomic analysis of biobank samples identified several proteins which were able to 
discriminate a healthy phenotype from early OA changes. Although these proteins 
were largely uncharacterised, BLAST analysis of the amino acid sequences of three 
uncharacterised proteins, decreasing in abundance with OA severity, identified high 
levels of similarity to immunoglobulin gamma 1 heavy chain constant region and 
immunoglobulin kappa chain V-III region MOPC 63 proteins. However, abundances 
of these uncharacterised proteins could not be validated using antibody 
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methodologies. Recently, a study investigating the SF proteome of a surgery-
induced OA model in rabbits identified reduced levels of immunoglobulin heavy chain 
protein compared to sham controls (69). Immunoglobulins have previously been 
identified within superficial articular cartilage layers of a proportion of OA patients as 
well as elevated levels found within the synovial membrane of dogs diagnosed with 
cranial cruciate ligament rupture (70, 71). Thus, reduction of these immunoglobulins 
within the SF may be reflective of their translocation to surrounding articular tissues. 
Glutamate is an excitatory amino acid neurotransmitter within the central nervous 
system, although evidence also suggests glutamate operates through intercellular 
signally cascades, as an autocrine/paracrine factor, in non-neuronal tissues (72). A 
self-sufficient glutamate signalling machinery has been identified within chondrocytes 
with a peripheral NMDA receptor proposed to have a role within inflammation and 
cartilage degradation (73). Within our study, the biobank group showed a reduction 
in synovial glutamate levels at higher OA severities. Previously, elevated levels of 
glutamate have been identified within OA SF of humans and within an OA rat models 
(74–76). However, no increase in glutamate was identified with equine OA SF using 
1H NMR, although it is not clear whether glutamate was identified during this study 
(32). The disparity between the lower glutamate levels identified within the biobank 
group and elevated levels within the literature may be reflective of the subtler OA 
phenotype exhibited by the biobank samples, and they may be indicative of 
glutamate levels at an earlier OA severity. However, the HKJC dataset, reflective of 
a higher grade OA, did not identify differential abundance. Therefore, at this stage 
the relationship between synovial glutamate abundance and equine OA remains 
inconclusive.  
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Creatine is a nonessential amino acid involved in cellular energy metabolism, 
maintaining cellular adenosine triphosphate (ATP) levels, in particular within the 
muscle and brain (77). Creatine SF levels increased with OA severity, which is 
supported by previous human and equine studies which also identified elevated SF 
creatine in OA SF (32, 78). Approximately 95% of stored creatine is located within 
skeletal muscle (79). Thus, given the association of muscle atrophy with OA, this 
elevation in synovial creatine may be reflective of an associated muscle mass loss 
(80). 
Within this study, alanine levels were identified to be increasing in SF in accordance 
with OA severity, which was also observed by Lacitignolia et al. (32). Previously, 
depleted alanine abundance has been identified within human OA cartilage using 
high resolution magic angle spinning NMR spectroscopy (81). As alanine is one of 
the main amino acid residues which constitutes collagen, it may be that the reduction 
in alanine abundance identified with OA cartilage is resultant of degradation of the 
cartilage collagen framework, which are subsequently released into the SF resulting 
in the elevated synovial abundance within this study (81, 82).  
Gelsolin (82-84 kDa) is a multifunctional, calcium ion-regulated actin filament 
severing, capping, and nucleating protein which is involved in the determination of 
cell shape, secretion and chemotaxis (83, 84). Previous studies of gelsolin on 
different biological systems have identified gelsolin as a potential predictor of both 
inflammation and tissue injury (85–87). Within rheumatoid arthritis patients, reduced 
circulating levels of plasma gelsolin have been identified (88). The authors propose 
this may be due to gelsolin redistribution to the affected joint space, binding to a 
plasma factor, reduced production or increased degradation. Within this study, SF 
gelsolin abundance was identified as decreasing with OA severity. Gelsolin was also 
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identified as having a significant correlation with OA severity and was found to be a 
highly influential factor when a model combining both biobank and HKJC datasets 
was developed. These results are supported by a mouse model whereby gelsolin 
knockout mice resulted in arthritis exacerbation (89). Additionally, within a mouse 
model of pain and acute inflammation, exogenous delivery of gelsolin was identified 
to have effective analgesic and anti-inflammatory properties (90). Exogenous 
gelsolin administration has also been shown to have chondroprotective properties, 
nullifying the effect of interleukin-1β and OA SF on anabolic gene expression and 
increased glycosaminoglycan deposition in chondrocytes and protection of the 
integrity of murine cartilage following intra-articular injection (84). Therefore, gelsolin 
has potential as a biomarker of equine OA as well as an OA therapeutic target, and 
potential analgesic. 
LBP is an endogenous protein which binds to lipopolysaccharides and catalytically 
delivers monomeric liposaccharides to cluster of differentiation 14 (CD14) protein 
(91, 92). Previously, serum and synovial levels of LBP were not identified to be 
differentially expressed between human degenerative arthropathy patients and 
control samples (93). However, increased plasma LBP levels have recently been 
described to predict knee OA progression (94). Within this current study, the trends 
identified suggest a decreasing SF abundance of LBP with increasing OA severity. It 
has previously been identified that mononuclear cell activation, induced by 
lipopolysaccharides, is enhanced by low LBP concentrations (95). Activation of 
monocytes and macrophages by lipopolysaccharides leads to the secretion of 
tumour necrosis factor alpha and interleukin-1 beta, two pro-inflammatory cytokines 
which are central to OA pathogenesis (96, 97). Thus, decreasing synovial LBP levels 
may have a role in OA development. With CD14 also identified as a key variable 
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within the biobank and HKJC combined model, this provides further support that this 
pathway is involved in equine OA pathogenesis. 
Elevations in synovial ApoA1 were identified in mild and moderate OA within the 
biobank group although abundance decreased for severe OA. Elevations in OA SF 
have previously been identified in horses and dogs (39, 98). ApoA1 is the primary 
protein component of high density lipoproteins (HDLs) and involved in HDL binding 
to ATP-binding cassette (ABC) transporters as well as being a lecithin cholesterol 
acyl transferase cofactor (99–102). ApoA1 has previously been found to induce the 
expression of interleukin-6, MMP-1 and MMP-3 in chondrocytes and synoviocytes 
through toll-like receptor 4 with the same study identifying a dissociation between the 
relationship of ApoA1 and HDLs in OA SF (103). When combining datasets within 
this study, apolipoprotein A-II (ApoA2) was also found to be an important variable. 
ApoA2 has previously been identified to be involved in the acute phase response 
which is associated with reactive amyloid A amyloidosis, via lipoprotein 
conformational changes, an associated complication of rheumatoid arthritis (104). 
Thus, this study provides further evidence that OA is a metabolic syndrome with 
disruption of lipid homeostasis due to alterations to apolipoprotein activity (103). 
Synovitis has previously been identified as an important aspect of OA pathogenesis 
(105–107). This study identified reduced synovial abundance of afamin in high grade 
synovitis compared to low grade. Similarly, reduced afamin levels have been 
recorded in equine OA SF compared to healthy joints (39). In a previous study 
however, elevated levels of afamin were identified within human knee OA SF (108). 
Afamin is a vitamin E binding glycoprotein and a member of the albumin gene family 
(109). Afamin forms a 1:1 complex with various hydrophobic Wnt proteins, 
solubilising the proteins and producing a biologically active complex (110). A growing 
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body of evidence has identified that the Wnt/β-catenin signalling cascade is likely to 
have a central role within OA pathogenesis (111). Thus, a reduction in synovial 
abundance of afamin may be reflective of a translocation following Wnt solubilisation 
to surrounding articular tissues, i.e. the synovium. However, it should be noted that a 
differential abundance of afamin was not identified when categorised according to 
OA severity. 
For the HKJC the semi-tryptic profile was most consistent between samples in the 
groups with the most severe OA and synovitis pathology. This suggests, as 
expected, the OA phenotype is driving the semi-tryptic peptide profile, most likely 
due to an increase in enzymatic activity leading to ECM degradation fragments 
(112). However, this was not evident within the biobank SF sample set. This may be 
because the OA pathology identified within this group was far subtler than that 
identified within the HKJC samples and thus the level of pathology present was not 
severe enough to drive a global change within the semi-tryptic peptide profile.  
Computational integration of separate ‘omics’ datasets can work synergistically, 
greatly enhancing the information that can be obtained from separate analyses 
(113). However, this poses the challenge of developing multi ‘omic’ integration 
techniques. Previously, a study carried out MS proteomic analysis comparing early 
and late stage human OA SF and combined this with transcriptomics of articular 
tissues to identify the source of differentially abundant synovial proteins (114). 
However, no previous studies have combined NMR metabolomics and MS proteomic 
datasets. 
Integrating the metabolomic and proteomic datasets separately for the biobank and 
HKJC both identified groupings associated with OA severity. Although correlation 
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values of variables to OA severity were generally low for the HKJC samples, 
stratification was still evident. Modelling was most robust for the biobank dataset, 
with the application of a Lasso model, with the model’s strength being the separation 
of more severe OA grades. However, within this sample set there were relatively few 
samples which were assigned to the higher OA severity grades compared to lower 
and is therefore a limitation of the model. Combining all results from both the biobank 
and HKJC datasets produced a model which was found to be highly accurate in 
correctly assigning samples within the mild OA group based on their integrated 
metabolomic and proteomic profiles. This is promising as mild OA recognition is the 
current unmet clinical need, aiding in early diagnosis and allowing for timely OA 
interventional management. However, the model is dominated by predominantly mild 
OA graded samples, and thus this will inevitably introduce bias into the model and 
make a correct reclassification of mild OA more likely. 
Within the combined dataset DAPC model, periostin was the principal driver of linear 
discriminant 2. Periostin is a 90 kDa matricellular protein which has regulatory 
functions in cell differentiation, cell adhesion and ECM organisation (115, 116). In 
human medicine, a positive correlation has been identified between both plasma and 
SF periostin abundance and knee OA severity (117). In-vivo results have identified 
that interleukin-13 may induce the production of periostin during OA, with periostin 
subsequently stimulating the production of MMPs within synoviocytes (118). In 
women, serum periostin levels were found to be associated with both prevalence 
and the risk of development/progression of knee OA (119). Thus for equids, periostin 
may also provide a potential therapeutic target and prognostic indicator. 
Protein pathway analysis identified the ‘complement and coagulation cascades’ 
pathway to be altered during OA pathology. Additionally, the uncharacterised protein 
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F6ZR63, the second most important variable of influence driving the biobank Lasso 
model, was found to have a high level of amino acid sequence similarity to 
complement factor H-like isoform X1. The complement system is an important 
component of the innate immune response, encompassing various roles including 
opsonisation initiation, pathogen phagocytosis, the inflammatory response and 
terminating within cell lysis (120, 121). However, a growing body of evidence has 
identified a role of complement activation within OA pathogenesis, which is further 
supported by this study (120). Complement has been identified to have a role in the 
degradation of cartilage ECM, synovitis and osteophyte formation, with complement 
split fragment C3a found to upregulate gene expression of tumour necrosis factor-α 
and Interleukin-1β, pro-inflammatory cytokines central to OA pathogenesis (97, 120). 
Therefore, targeting the complement cascade may provide a novel therapeutic target 
for OA treatment. 
Within experimental arthritis models, coagulation and fibrinolysis pathways are 
known to play a role within disease pathogenesis, with these cascades also found to 
be activated within both the joint and circulation of degenerative and inflammatory 
arthropathies (122). Within the synovium of patients diagnosed with OA, the 
coagulation factor fibrinogen is present throughout the tissue with elevations in tissue 
factor, a coagulation initiator, identified near endothelial cells (123). Previously, 
fibrinogen has been identified as a potential target for arthritis therapy, with removal 
of fibrinogen-leukocyte integrin receptor αMβ2 interactions limiting inflammatory 
processes whilst maintaining normal fibrinogen coagulation function (124). Thus 
these pathways may also hold potential as a novel target for OA therapy. 
Metabolite pathway analysis identified the ‘ABC transporters’ pathway to be altered 
during OA pathology. ABC transporters utilise ATP hydrolysis to import or export 
Stratification of Equine Osteoarthritis 
31 
 
molecules across cell membranes (125). ABC exporters have an important role in 
the export of cholesterol, fatty acid and lipids from cells, with dysregulation of this 
pathway underlying numerous diseases. The Wnt/β-catenin signalling cascade, with 
a proposed central role within OA pathogenesis, has previously been identified as a 
regulator of ABC transporters (126). Additionally, the ABC transporter MRP5 has 
been found to be the principal exporter of hyaluronan from its site of synthesis within 
the cell to the ECM (127). However, as only four key metabolites were identified 
within this pathway, caution should be applied when analysing these results to avoid 
over interpretation. 
Further Work 
Several proteins of interest identified within this study were uncharacterised. BLAST 
amino acid sequence analysis of similar proteins provided further information on their 
potential function, however this could be taken further by conducting 3D modelling of 
these proteins to help confirm function and potential interactions with other 
proteins/molecules. Additionally, developing monoclonal antibodies which are 
specific to these uncharacterised proteins would allow this methodology to provide 
an orthologous method to confirm protein abundances. Within the cohorts used in 
this study, there was an over-representation of mild OA diagnoses opposed to more 
severe phenotypes. Although this is advantageous in terms of identifying early OA 
markers, in order to fully stratify OA, the addition of a greater number of donors with 
higher grade OA would provide a more comprehensive synovial profile of the 
metabolite and protein profiles at differing OA grades and provide more robust 
models. As this study adopted a cross-sectional approach, further work of interest 
would be to conduct repeated measures within a longitudinal study to discover 
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whether the identified markers of interest validate this study’s findings. Also, given 
the differential abundance of ApoA1 and LBP identified within this study, it would be 
of interest to further interrogate SF, using both NMR and MS based approaches, to 
investigate the lipid profile and identify changes during OA progression. 
Conclusions 
In conclusion, this study has stratified equine OA using both metabolomic and 
proteomic SF profiles and identified a panel of markers of interest which may be 
applicable to grading OA severity. This is also the first study to undertake 
computational integration of NMR metabolomic and LC-MS/MS proteomic datasets 
of any biological system. 
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Tables 
Table 1. Stratification groups according to microscopic osteoarthritis, macroscopic osteoarthritis and synovitis pathology used for 
synovial fluid LC-MS/MS proteomic and NMR metabolomic analysis. 
 
Abbreviations: OA = Osteoarthritis; Joints, MCP = Metacarpophalangeal joint, MTP = Metatarsophalangeal joint; Sex, M = male, F 
= Female.
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Table 2. Synovial fluid metabolites identified using Chenomx software. Metabolites 
which had also undergone identification using a 1D 1H NMR in-house spectral library 
were assigned to Metabolomics Standards Initiative (MSI) level 1 (129). 
 
Database 
Identifier 
Metabolite 
Identification 
Reliability 
HMDB00650 2-Aminobutyrate MS Level 2 
HMDB00357 3-Hydroxybutyrate MS Level 2 
HMDB00754 3-Hydroxyisovalerate MS Level 2 
HMDB01149 5-Aminolevulinate MS Level 2 
HMDB00042 Acetate MS Level 1 
HMDB00194 Anserine MS Level 2 
HMDB00043 Betaine MS Level 1 
HMDB00097 Choline MS Level 1 
HMDB00094 Citrate MS Level 1 
HMDB00064 Creatine MS Level 1 
HMDB01511 Creatine phosphate MS Level 2 
HMDB00562 Creatinine MS Level 1 
HMDB00122 D-Glucose MS Level 1 
HMDB04983 Dimethyl sulfone MS Level 2 
HMDB00142 Formate MS Level 2 
HMDB00123 Glycine MS Level 1 
HMDB00128 Guanidoacetate MS Level 2 
HMDB00172 Isoleucine MS Level 1 
HMDB00190 Lactate MS Level 1 
HMDB00161 L-Alanine MS Level 1 
HMDB00062 L-Carnitine MS Level 2 
HMDB00174 L-Fucose MS Level 2 
HMDB00148 L-Glutamate MS Level 1 
HMDB00641 L-Glutamine MS Level 1 
HMDB00177 L-Histidine MS Level 1 
HMDB00687 L-Leucine MS Level 1 
HMDB00159 L-Phenylalanine MS Level 1 
HMDB00158 L-Tyrosine MS Level 1 
HMDB00883 L-Valine MS Level 1 
HMDB00691 Malonate MS Level 2 
HMDB01844 Methylsuccinate MS Level 2 
HMDB31419 N-Nitrosodimethylamine MS Level 2 
HMDB00895 O-Acetylcholine MS Level 2 
HMDB00243 Pyruvate MS Level 1 
HMDB00254 Succinate MS Level 1 
HMDB00294 Urea MS Level 1 
HMDB00296 Uridine MS Level 1 
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HMDB00292 Xanthine MS Level 2 
HMDB00001 π-Methylhistidine MS Level 2 
HMDB00001 τ-Methylhistidine MS Level 2 
 
Metabolomics Standards Initiative definitions: MS Level 1 = Identified metabolite 
using two or more orthogonal properties of an authentic chemical standard analysed 
in the researcher’s laboratory. MS Level 2 = Putatively annotated metabolite which 
does not require matching to data for authentic chemical standards acquired within 
the same laboratory. 
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Table 3. Pathway analysis conducted on proteins which were considered significant 
variables during DAPC modelling, when carrying out NMR metabolomic and LC-
MS/MS proteomic dataset integration. 
 
Pathway 
ID 
Pathway Description 
Number of 
Proteins in 
Pathway 
False 
Discovery 
Rate 
4610 Complement and coagulation cascades 7 0.00000573 
4145 Phagosome 6 0.00498 
4390 Hippo signalling pathway 5 0.0188 
 
Table 4. Pathway analysis conducted on metabolites which were considered 
significant variables during DAPC modelling, when carrying out NMR metabolomic 
and LC-MS/MS proteomic dataset integration. 
 
Pathway ID Pathway Description 
Number of 
Metabolites in 
Pathway 
2010 ABC transporters  4 
4978 Mineral absorption  3 
10 Glycolysis / Gluconeogenesis 2 
4974 Protein digestion and absorption 2 
340 Histidine metabolism 2 
4066 HIF-1 signalling pathway 2 
4976 Bile secretion 2 
4922 Glucagon signalling pathway 2 
970 Aminoacyl-tRNA biosynthesis 2 
1230 Biosynthesis of amino acids 2 
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Figures and Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Principal component analysis (PCA) of metabolite profiles of equine 
biobank synovial fluid grouped according to (A) OARSI microscopic (n=70) and (B) 
OARSI macroscopic (n=76) grading. (C) Glutamate abundances according to 
macroscopic osteoarthritis grading. ANOVA: ** = p < 0.01 and *** = p < 0.001. 
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Figure 2. Principal component analysis (PCA) of metabolite profiles of equine Hong 
Kong Jockey Club (HKJC) synovial fluid (SF) grouped according to (A) OARSI 
microscopic (n=50), (B) OARSI macroscopic (n=50) and (C) synovitis (n=56) 
grading. For OARSI macroscopic grading, (D) 2-aminobutyrate, (E) alanine and (F) 
creatine were identified as being differentially abundant between osteoarthritis 
severity grades. ANOVA: * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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Figure 3. Number of proteins identified within native and ProteoMinerTM processed 
equine synovial fluid using liquid chromatography-tandem mass spectrometry. In 
total, 1,834 different proteins were identified. Search criteria included > 2 unique 
peptides with an FDR of 1%. LC = liquid chromatography. 
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Figure 4. Principal component analysis (PCA) of the biobank native synovial fluid 
proteome categorised by (A) macroscopic osteoarthritis (OA) grade and (B) 
microscopic OA grade using LC-MS/MS. (C-H) Differentially expressed proteins 
when categorised according to macroscopic OA grade. ANOVA: * = p < 0.05, ** = p 
< 0.01, *** = p < 0.001. Macroscopic OA, n=66, Microscopic OA, n=70. 
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Figure 5. Principal component analysis (PCA) of the Hong Kong Jockey Club 
(HKJC) native synovial fluid proteome profile categorised by (A) macroscopic 
osteoarthritis (OA) grade (n=49), (B) microscopic OA grade (n=49) and (C) synovitis 
grade (n=53) using LC-MS/MS. (D) Differential expression of afamin identified 
between synovitis grade 1 and 2. t-test: * = p < 0.05. 
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Figure 6. Abundances of gelsolin, lipopolysaccharide binding protein (LBP) and 
apolipoprotein A1 (ApoA1) within equine synovial fluid via LC-MS/MS (A, D & G) and 
ELISA validation using dependent (B, E & H) and independent (C & F) synovial fluid 
samples according to osteoarthritis (OA) grade. LC-MS/MS; HKJC, n=47; Biobank, 
n=60; ELISA, n=3-6/group. ANOVA and t-tests: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. LC-MS/MS p values corrected for multiple testing within sample, but not for 
entire dataset. 
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Figure 7. Principal component analysis (PCA) using 58 selected variables (proteins 
and metabolites) for the Hong Kong Jockey Club synovial fluid combined datasets 
(n=43) following batch correction, grouped according to macroscopic osteoarthritis 
score. OA = osteoarthritis. 
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Figure 8. (A) Principal component analysis (PCA) following Lasso model selection 
using the top 29 variables of influence for biobank synovial fluid, integrating 
metabolite and protein abundances and grouped according to macroscopic 
osteoarthritis scoring. (B) Top 14 variables of influence contributing to the model. 
n=60. 
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Figure 9. (A) Discriminant analysis of principal components (DAPC) of selected 
variables (proteins and metabolites) for a combined biobank and Hong Kong Jockey 
Club synovial fluid dataset (n=103), built using 20 principal components and two 
linear discriminants. (B) Top 25% of variables for the DAPC model contributing to 
linear discriminant 1 and (C) linear discriminant 2. Macroscopic osteoarthritis (OA) 
scoring; Healthy = 0, Mild OA = 1-3, Severe OA = 4-8. 
 
 
 
 
 
 
 
 
 
